Hairloss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.
Hairfollicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.
PP405 is a potential hairloss treatment that may activate dormant hairfollicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.
PP405 is a new hairloss treatment targeting dormant hairfollicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
Hairloss treatments like Minoxidil, finasteride, and stem cell therapies exist, but a complete cure is hindered by genetic complexity and market dynamics. Cloning hairfollicles is considered a potential solution, but it's currently not feasible.
Excess sebum rich in cholesterol and triglycerides can lead to hairloss through inflammation, with treatments like Ciclopirox shampoo, Benzoyl Peroxide shampoo, and Clindamycin gel recommended for managing conditions like seborrheic dermatitis and folliculitis. Pioglitazone is suggested for Lichen Planopilaris, while Omega-3s and reducing processed foods may improve sebum quality, though genetic factors play a significant role.
Hairfollicle cloning is claimed to be possible but not widely available due to potential safety issues, such as cancer risks. Current treatments like finasteride and dutasteride are not effective for everyone, and there is frustration over limited access to these medications.
TWIST-1 gene's role in hairloss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hairfollicle sensitivity to DHT.
The conversation discusses the complexity of hairloss causes, suggesting that DHT sensitivity alone doesn't fully explain it. Treatments mentioned include finasteride and dutasteride.
A user plans to experiment with creating new hairfollicles using methods like derma rolling, applying lithium chloride, tannic acid, and various other substances including caffeine, ketoconazole, and raspberry ketones. They also consider using anti-inflammatories, immunosuppressants, and DHT inhibitors to potentially improve results.
Hairloss treatments discussed include minoxidil, finasteride, dutasteride RU, derma rolling, pyrilutamide, cosmeRNA, hair systems, and essential oils. The user seeks information on additional treatments, safety profiles, and alternative options for androgenetic alopecia.
PP405 is a potential hairloss treatment that may reactivate dormant hairfollicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.
The conversation discusses affordable hairloss treatments, including topical finasteride, minoxidil, tretinoin, and natural remedies like castor and peppermint oil. Specific treatments for hairloss are the focus.
Hairloss may be caused by calcification of capillaries in the scalp, restricting blood flow to hairfollicles. A daily treatment regimen including high doses of Vitamins D and K, Magnesium, and Nattokinase could potentially decalcify these capillaries, improving blood flow and hair growth. However, some users warn against excessive Vitamin D intake and emphasize the need for medical consultation.
Hairloss treatments like Minoxidil and Finasteride will still be used even if a cure is found. Hair transplants will continue as cloning new hairfollicles will be part of the process.
AMP-303 and AMP-601 are new hairloss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
Hairloss treatments include topical and oral minoxidil, low-level laser light therapy, and peptide serums. Bryan Johnson avoids finasteride and dutasteride due to potential side effects, focusing instead on his own protocol with these treatments.
Hairloss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hairloss, unlike Pelage's PP405.
PP405 is a promising new hairloss treatment that may reactivate dormant hairfollicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.
Hairfollicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.
Adipose-derived stem cell secretome showed significant improvement in hair density and growth, especially when combined with minoxidil, suggesting a synergistic effect. The study had limitations, including a small sample size and potential bias.
Feeding bacteria-free mice with Lactobacillus murinus worsened hairloss, but a regular diet with biotin stopped it. The conversation suggests gut bacteria and diet may influence hairloss, with some skepticism and discussion about other factors like DHT and genetics.
Hair growth relies on mechanical forces, not just chemicals, with tissue acting like a motor. Minoxidil and finasteride help, but maintaining tissue elasticity and addressing mechanical issues are essential.
Hairloss is linked to scalp fibrosis and tension, which result from chronic mechanical stress and androgenic signaling. Treatments include blocking androgens with finasteride, promoting hair growth with topical minoxidil, and improving scalp mobility through exercises.
New hairloss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.
The conversation discusses potential hairloss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.